Production (Stage)
Chemomab Therapeutics Ltd.
CMMB
$1.23
$0.032.50%
NASDAQ
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -- | 77.33% | 50.57% | 12.39% | -97.10% |
| Total Depreciation and Amortization | -- | -44.44% | -16.39% | 15.52% | 52.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -86.37% | -64.30% | -53.57% | -1.02% |
| Change in Net Operating Assets | -- | -139.38% | -144.11% | -123.66% | 353.22% |
| Cash from Operations | -- | 65.12% | 31.12% | -15.91% | -61.20% |
| Capital Expenditure | -- | 100.00% | 96.36% | 95.59% | 78.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -77.71% | -95.42% | -18.97% | 172.64% |
| Cash from Investing | -- | -77.67% | -95.42% | -18.71% | 173.79% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 21.64% | 754.63% | 754.63% | -96.95% |
| Repurchase of Common Stock | -- | -- | -- | -- | -696.08% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 297.03% | 533.66% | 533.66% | -106.09% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -319.35% | -265.57% | -157.02% | 115.64% |